0      0

AONN+ 2022 Annual Conference

Product Theater 4| EXKIVITY® (mobocertinib): The first and only oral therapy designed to target EGFR Exon20 Insertion+ mNSCLC Presentation by Takeda


Nov 4, 2022 3:45pm ‐ Nov 4, 2022 4:45pm


Speaker(s):

You must be logged in and own this session in order to post comments.